MedPath

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Phase 2
Completed
Conditions
Congestive Heart Failure
First Posted Date
2002-08-14
Last Posted Date
2005-06-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
170
Registration Number
NCT00043758
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Midwest Cardiology Research Foundation, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Guthrie Clinic, LTD, Sayre, Pennsylvania, United States

and more 37 locations

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Phase 2
Completed
Conditions
Congestive Heart Failure
First Posted Date
2002-08-14
Last Posted Date
2005-06-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
40
Registration Number
NCT00043771
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Central Cardiology Medical Clinic, Bakersfield, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis University, St. Louis, Missouri, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California-San Diego, San Diego, California, United States

and more 6 locations

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
2002-07-15
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00041678
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Milwaukee, Wisconsin, United States

Study of Aripiprazole in Patients With a History of Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2002-05-10
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036348
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, San Antonio, Texas, United States

Broad Effectiveness: Study With Aripiprazole

Phase 3
Completed
Conditions
Schizoaffective Disorder
Schizophrenia
First Posted Date
2002-05-10
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
444
Registration Number
NCT00036361
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Wallingford, Connecticut, United States

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2002-05-09
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036101
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Bellevue, Washington, United States

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
2002-05-09
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036114
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Seattle, Washington, United States

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Phase 2
Completed
Conditions
Schizophrenia
First Posted Date
2002-05-09
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036127
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Instituton, Hoffman Estates, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Milwaukee, Wisconsin, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath